Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Iman Fathy Abou-El-Naga, Maha Mohamed Gomaa & Samar Nabil ElAchy. (2022) Effect of HIV aspartyl protease inhibitors on experimental infection with a cystogenic Me49 strain of Toxoplasma gondii. Pathogens and Global Health 116:2, pages 107-118.
Read now
Read now
José Vicente Fernández-Montero, Eugenia Vispo & Vicente Soriano. (2014) Emerging antiretroviral drugs. Expert Opinion on Pharmacotherapy 15:2, pages 211-219.
Read now
Read now
Jose V Fernandez-Montero, Eugenia Eugenia, Pablo Barreiro, Pablo Labarga & Vicente Soriano. (2013) Antiretroviral drug-related toxicities – clinical spectrum, prevention, and management. Expert Opinion on Drug Safety 12:5, pages 697-707.
Read now
Read now
C. Tremblay, B. Trottier, A. Rachlis, J.G. Baril, M. Loutfy, R. Lalonde, J.S. Sampalis & F. Boulerice. (2011) Treatment Durability, Effectiveness, and Safety with Atazanavir/Ritonavir-Based HAART Regimen in Treatment-Naïve HIV-lnfected Patients. HIV Clinical Trials 12:3, pages 151-160.
Read now
Read now
Miguel Ángel Artacho, Pablo Barreiro & José Vicente Fernández-Montero. (2010) Long-term treatment of patients with HIV-1: the role of atazanavir. HIV/AIDS - Research and Palliative Care 2, pages 157-166.
Read now
Read now
Articles from other publishers (28)
Sónia Soares, Mélina Bornet, Clara Grosso, Maria João Ramalhosa, Irene Gouvinhas, Juliana Garcia, Francisca Rodrigues & Cristina Delerue-Matos. (2022) Honey as an Adjuvant in the Treatment of COVID-19 Infection: A Review. Applied Sciences 12:15, pages 7800.
Crossref
Crossref
Seyed Ali Hemmati & Saeid Tabein. (2022) Insect protease inhibitors; promising inhibitory compounds against SARS-CoV-2 main protease. Computers in Biology and Medicine 142, pages 105228.
Crossref
Crossref
Shreyas Kaptan, Mykhailo Girych, Giray Enkavi, Waldemar Kulig, Vivek Sharma, Joni Vuorio, Tomasz Rog & Ilpo Vattulainen. (2022) Maturation of the SARS-CoV-2 virus is regulated by dimerization of its main protease. Computational and Structural Biotechnology Journal 20, pages 3336-3346.
Crossref
Crossref
Monica Florin-Christensen, Sarah N. Wieser, Carlos E. Suarez & Leonhard Schnittger. (2021) In Silico Survey and Characterization of Babesia microti Functional and Non-Functional Proteases. Pathogens 10:11, pages 1457.
Crossref
Crossref
Essa M. Saied, Yousra A. El-Maradny, Alaa A. Osman, Amira M. G. Darwish, Hebatallah H. Abo Nahas, Gniewko Niedbała, Magdalena Piekutowska, Mohamed A. Abdel-Rahman, Bassem A. Balbool & Ahmed M. Abdel-Azeem. (2021) A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19. Pharmaceutics 13:11, pages 1759.
Crossref
Crossref
Jiangnan Dong, Su Li & Guangxuan Liu. (2021) Binimetinib Is a Potent Reversible and Time-Dependent Inhibitor of Cytochrome P450 1A2. Chemical Research in Toxicology 34:4, pages 1169-1174.
Crossref
Crossref
Nakarin Suwannarach, Jaturong Kumla, Kanaporn Sujarit, Thanawat Pattananandecha, Chalermpong Saenjum & Saisamorn Lumyong. (2020) Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses. Molecules 25:8, pages 1800.
Crossref
Crossref
Eva Agnes Odongpiny Laker, Maria Sarah Nabaggala, Arvind Kaimal, Damalie Nalwanga, Barbara Castelnuovo, Abdu Musubire, Agnes Kiragga, Mohammed Lamorde & Rosalind Parkes- Ratanshi. (2019) An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir. BMC Infectious Diseases 19:1.
Crossref
Crossref
Xiucai Guo, Wei Li, Qingmei Li, Yan Chen, Guode Zhao, Ying Peng & Jiang Zheng. (2019) Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4. Chemical Research in Toxicology 32:9, pages 1791-1800.
Crossref
Crossref
Ayodeji A. Agbowuro, Wilhelmina M. Huston, Allan B. Gamble & Joel D. A. Tyndall. (2018) Proteases and protease inhibitors in infectious diseases. Medicinal Research Reviews 38:4, pages 1295-1331.
Crossref
Crossref
Iman Fathy Abou-El-Naga, Eman Dorry El Kerdany, Rasha Fadly Mady, Thanaa Ibrahim Shalaby & Enas Mohammed Zaytoun. (2017) The effect of lopinavir/ritonavir and lopinavir/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis. Parasitology International 66:6, pages 735-747.
Crossref
Crossref
Biswajit G Roy. (2017) Potential of small-molecule fungal metabolites in antiviral chemotherapy. Antiviral Chemistry and Chemotherapy 25:2, pages 20-52.
Crossref
Crossref
Carlos Brites, Isabella Nóbrega & Eduardo Martins Netto. (2015) Use of new antiretroviral drugs and classes in Bahia, Brazil: a real life experience on salvage therapy of AIDS patients. The Brazilian Journal of Infectious Diseases 19:5, pages 529-532.
Crossref
Crossref
Brooke M. Rock, Shawna M. Hengel, Dan A. Rock, Larry C. Wienkers & Kent L. Kunze. (2014) Characterization of Ritonavir-Mediated Inactivation of Cytochrome P450 3A4. Molecular Pharmacology 86:6, pages 665-674.
Crossref
Crossref
Maren Kuhnert, Holger Steuber & Wibke E. Diederich. (2014) Structural Basis for HTLV-1 Protease Inhibition by the HIV-1 Protease Inhibitor Indinavir. Journal of Medicinal Chemistry 57:14, pages 6266-6272.
Crossref
Crossref
Georgio Kourjian, Yang Xu, Ijah Mondesire-Crump, Mariko Shimada, Pauline Gourdain & Sylvie Le Gall. (2014) Sequence-Specific Alterations of Epitope Production by HIV Protease Inhibitors. The Journal of Immunology 192:8, pages 3496-3506.
Crossref
Crossref
Kirsten M. Stray, Christian Callebaut, Bärbel Glass, Luong Tsai, Lianhong Xu, Barbara Müller, Hans-Georg Kräusslich & Tomas Cihlar. (2013)
Mutations in Multiple Domains of Gag Drive the Emergence of
In Vitro
Resistance to the Phosphonate-Containing HIV-1 Protease Inhibitor GS-8374
. Journal of Virology 87:1, pages 454-463.
Crossref
Crossref
Olawale Ajose, Siddharth Mookerjee, Edward J. Mills, Andrew Boulle & Nathan Ford. (2012) Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings. AIDS 26:8, pages 929-938.
Crossref
Crossref
Filippo Canducci, Elisa Rita Ceresola, Diego Saita, Yousef Al-Abed, Gianni Garotta, Massimo Clementi & Ferdinando Nicoletti. (2011) The new and less toxic protease inhibitor saquinavir–NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir. Antiviral Research 91:3, pages 292-295.
Crossref
Crossref
Jinzi J. Wu & Joseph Musto. 2011. Antiviral Drugs. Antiviral Drugs
19
30
.
Alessandra Viganò, Valeria Manfredini, Francesca Penagini, Vania Giacomet & Gian Vincenzo Zuccotti. (2011) Antiretroviral drugs in HIV-infected children. Pharmacological Research 64:1, pages 1-3.
Crossref
Crossref
Prasenjit Mukherjee, Falgun Shah, Prashant Desai & Mitchell Avery. (2011)
Inhibitors of SARS-3CL
pro
: Virtual Screening, Biological Evaluation, and Molecular Dynamics Simulation Studies
. Journal of Chemical Information and Modeling 51:6, pages 1376-1392.
Crossref
Crossref
Sérgio Filipe Sousa, Bruno Tamames, Pedro Alexandrino Fernandes & Maria João Ramos. (2011) Detailed Atomistic Analysis of the HIV-1 Protease Interface. The Journal of Physical Chemistry B 115:21, pages 7045-7057.
Crossref
Crossref
Vicente Soriano, Keikawus Arastéh, Horacio Migrone, Thomas Lutz, Milos Opravil, Jaime Andrade-Villanueva, Francisco Antunes, Giovanni Di Perri, Daniel Podzamczer, Steve Taylor, Pere Domingo, Holger Gellermann & Lothar de Rossi. (2010) Nevirapine versus Atazanavir/Ritonavir, Each Combined with Tenofovir Disoproxil Fumarate/Emtricitabine, in Antiretroviral-Naive HIV-1 Patients: The Arten Trial. Antiviral Therapy 16:3, pages 339-348.
Crossref
Crossref
Paul W. Hruz, Qingyun Yan, Luong Tsai, Joseph Koster, Lianhong Xu, Tomas Cihlar & Christian Callebaut. (2011) GS-8374, a Novel HIV Protease Inhibitor, Does Not Alter Glucose Homeostasis in Cultured Adipocytes or in a Healthy-Rodent Model System. Antimicrobial Agents and Chemotherapy 55:4, pages 1377-1382.
Crossref
Crossref
Erdembileg Anuurad, Andrew Bremer & Lars Berglund. (2010) HIV protease inhibitors and obesity. Current Opinion in Endocrinology, Diabetes and Obesity 17:5, pages 478-485.
Crossref
Crossref
Judit Morello, Sonia Rodríguez-Novoa, Francisco Blanco, Eugenia Vispo, Pablo Barreiro, Gema Gonzalez-Pardo, Inmaculada Jiménez-Nácher, Juan González-Lahoz & Vincent Soriano. (2010) The Benefit of Simplification From Tipranavir/Ritonavir 500/200 bid to 500/100 bid Guided by Therapeutic Drug Monitoring. Therapeutic Drug Monitoring 32:2, pages 242-244.
Crossref
Crossref
Jana Pokorná, Ladislav Machala, Pavlína Řezáčová & Jan Konvalinka. (2009) Current and Novel Inhibitors of HIV Protease. Viruses 1:3, pages 1209-1239.
Crossref
Crossref